Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta ’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Regulatory action date of May 29, 2023 SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional shortened dystrophin to muscle CAMBRIDGE, Mass., Nov....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news